Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,580 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: patch Clear all

Conditions: Solid Tumors, Soft Tissue Sarcoma, Ewing Sarcoma, Malignant Epithelial Neoplasm, Rhabdomyosarcoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Bone Metastases
Interventions: Magnetic Resonance-Guided High Intensity Focused Ultrasound, Lyso-thermosensitive Liposomal Doxorubicin; Device · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Von-Hippel Lindau, Kidney Disease, Chronic
Interventions: Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 16 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Tobacco Use Disorder
Interventions: Cognitive Behavioral Therapy for Smoking Cessation, Nicotine Replacement Therapy, Bupropion, Varenicline, Mobile Contingency Management, Clinic-Based Smoking Cessation Counseling; Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cardiovascular Diseases, Peripheral Vascular Disease, Arterial Occlusive Diseases, Peripheral Arterial Disease, Critical Limb Ischemia
Interventions: Paclitaxel administration using the OPC; Other
Lead sponsor: Horizons International Peripheral Group; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Fairhope, Alabama • Houma, Louisiana • Dearborn, Michigan + 1 more

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: Breast Diseases
Interventions: SAVI SCOUT Surgical Guidance System; Device
Lead sponsor: Envision Healthcare Scientific Intelligence, Inc.; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Osteoarthritis
Interventions: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System), Placebo Matrix/CHADD Patch, Ketoprofen matrix/placebo CHADD Patch; Drug
Lead sponsor: ZARS Pharma Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Peoria, Arizona • Anaheim, California • Buena Park, California + 33 more

Conditions: Anxiety, Sleep
Interventions: Active dermal patch, Placebo patch; Device
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Menorrhagia
Interventions: NovaSure Endometrial Ablation; Device
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 14
States / cities: Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more

Conditions: Smoking
Interventions: Positive Psychotherapy for smoking cessation, Nicotine polacrilex, Relaxation training, Behavioral smoking cessation treatment; Behavioral · Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Pigmented Skin Lesion
Interventions: FRAX 1940 nm laser; Device
Lead sponsor: Candela Corporation; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Keratosis, Actinic
Interventions: Swift System; Device
Lead sponsor: Blackwell Device Consulting; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Peripheral Pulmonary Lesions
Interventions: ILLUMISITE™ Platform (EMN bronchoscopy), Ion™ Endoluminal System (SSCB bronchoscopy); Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: ECG Effects
Interventions: Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 328 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Intracranial Atherosclerosis
Interventions: Wingspan Stent System; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: Not listed
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Castro Valley, California • Los Angeles, California + 21 more

Conditions: Neurofibromatosis 2, Vestibular Schwannoma, Meningioma, Ependymoma, Glioma
Interventions: Selumetinib; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years to 45 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer, Pituitary Adenoma
Interventions: Panitumumab-IRDye800; Drug
Lead sponsor: Eben Rosenthal; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Smoking Cessation
Interventions: Spotlight on Smoke-Free Living: Mindsets and Decisions, Transdermal Nicotine Patch; Behavioral · Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Atrial Fibrillation, Maze Procedure, AF, Ablation
Interventions: CellFX® nsPFA™ Cardiac Surgery System; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: St. Helena, California • Orlando, Florida • Ann Arbor, Michigan

Conditions: Smoking Cessation
Interventions: Contingency management, Nicotine replacement therapy, Varenicline, Additional behavioral support; Behavioral · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Colorectal Neoplasm, Colonic Polyps
Interventions: Close focus HD NBI Colonoscopy System; Device
Lead sponsor: VA Palo Alto Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Palo Alto, California • Kansas City, Missouri

Conditions: Actinic Keratosis
Interventions: Lesion count; Drug
Lead sponsor: Peplin; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 17
States / cities: Hot Springs, Arizona • San Diego, California • Alpharetta, Georgia + 14 more

Conditions: Human Papillomavirus, HPV-16, High Grade Squamous Intraepithelial Lesion
Interventions: Aldesleukin, E6 T Cell Receptor (TCR); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma
Interventions: Lenalidomide; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors

Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

The COPPER-B Trial

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Long Term Use of SAVI SCOUT: Pilot Study

Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee

Longterm Effects of a Biofield Patch on Anxiety, Sleep, and Energy

Post Approval NovaSure Essure Labeling Study

Development of Positive Psychotherapy for Smoking Cessation

Nonablative Fractional Diode Laser for Treatment of Pigmented Lesions

Microwave Treatment for Actinic Keratosis

Robotic Versus Electromagnetic Bronchoscopy for Pulmonary LesIon AssessmeNT: (the RELIANT Trial)

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

Post Market Surveillance Study of the Wingspan Stent System

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures

Smoking Cessation Intervention

CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation

A Smoking Cessation Intervention for Yale Dining Employees

Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study

A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study

Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions

Maintenance Lenalidomide in Lymphoma